491 related articles for article (PubMed ID: 26810733)
1. EBI-907, a novel BRAF(V600E) inhibitor, has potent oral anti-tumor activity and a broad kinase selectivity profile.
Zhang J; Lu B; Liu D; Shen R; Yan Y; Yang L; Zhang M; Zhang L; Cao G; Cao H; Fu B; Gong A; Sun Q; Wan H; Zhang L; Tao W; Cao J
Cancer Biol Ther; 2016; 17(2):199-207. PubMed ID: 26810733
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
[TBL] [Abstract][Full Text] [Related]
3. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
4. BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.
Tang Z; Yuan X; Du R; Cheung SH; Zhang G; Wei J; Zhao Y; Feng Y; Peng H; Zhang Y; Du Y; Hu X; Gong W; Liu Y; Gao Y; Liu Y; Hao R; Li S; Wang S; Ji J; Zhang L; Li S; Sutton D; Wei M; Zhou C; Wang L; Luo L
Mol Cancer Ther; 2015 Oct; 14(10):2187-97. PubMed ID: 26208524
[TBL] [Abstract][Full Text] [Related]
5. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.
Prahallad A; Sun C; Huang S; Di Nicolantonio F; Salazar R; Zecchin D; Beijersbergen RL; Bardelli A; Bernards R
Nature; 2012 Jan; 483(7387):100-3. PubMed ID: 22281684
[TBL] [Abstract][Full Text] [Related]
6. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.
Krayem M; Journe F; Wiedig M; Morandini R; Najem A; Salès F; van Kempen LC; Sibille C; Awada A; Marine JC; Ghanem G
Eur J Cancer; 2016 Mar; 55():98-110. PubMed ID: 26790143
[TBL] [Abstract][Full Text] [Related]
7. A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in Mice.
Feng JH; Nakagawa-Goto K; Lee KH; Shyur LF
Mol Cancer Ther; 2016 Jun; 15(6):1163-76. PubMed ID: 27048951
[TBL] [Abstract][Full Text] [Related]
8. Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting.
Carroll MJ; Parent CR; Page D; Kreeger PK
BMC Cancer; 2019 Oct; 19(1):1025. PubMed ID: 31672130
[TBL] [Abstract][Full Text] [Related]
9. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.
Sun C; Wang L; Huang S; Heynen GJ; Prahallad A; Robert C; Haanen J; Blank C; Wesseling J; Willems SM; Zecchin D; Hobor S; Bajpe PK; Lieftink C; Mateus C; Vagner S; Grernrum W; Hofland I; Schlicker A; Wessels LF; Beijersbergen RL; Bardelli A; Di Nicolantonio F; Eggermont AM; Bernards R
Nature; 2014 Apr; 508(7494):118-22. PubMed ID: 24670642
[TBL] [Abstract][Full Text] [Related]
10. Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma.
Tahiri A; Røe K; Ree AH; de Wijn R; Risberg K; Busch C; Lønning PE; Kristensen V; Geisler J
PLoS One; 2013; 8(8):e72692. PubMed ID: 24023633
[TBL] [Abstract][Full Text] [Related]
11. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
[TBL] [Abstract][Full Text] [Related]
12. Targeting of super-enhancers and mutant BRAF can suppress growth of BRAF-mutant colon cancer cells via repression of MAPK signaling pathway.
Nakamura Y; Hattori N; Iida N; Yamashita S; Mori A; Kimura K; Yoshino T; Ushijima T
Cancer Lett; 2017 Aug; 402():100-109. PubMed ID: 28576751
[TBL] [Abstract][Full Text] [Related]
13.
Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
[No Abstract] [Full Text] [Related]
14. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
[TBL] [Abstract][Full Text] [Related]
15. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.
Mao M; Tian F; Mariadason JM; Tsao CC; Lemos R; Dayyani F; Gopal YN; Jiang ZQ; Wistuba II; Tang XM; Bornman WG; Bollag G; Mills GB; Powis G; Desai J; Gallick GE; Davies MA; Kopetz S
Clin Cancer Res; 2013 Feb; 19(3):657-67. PubMed ID: 23251002
[TBL] [Abstract][Full Text] [Related]
16. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
[TBL] [Abstract][Full Text] [Related]
17. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.
Girotti MR; Pedersen M; Sanchez-Laorden B; Viros A; Turajlic S; Niculescu-Duvaz D; Zambon A; Sinclair J; Hayes A; Gore M; Lorigan P; Springer C; Larkin J; Jorgensen C; Marais R
Cancer Discov; 2013 Feb; 3(2):158-67. PubMed ID: 23242808
[TBL] [Abstract][Full Text] [Related]
18. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).
Poulikakos PI; Persaud Y; Janakiraman M; Kong X; Ng C; Moriceau G; Shi H; Atefi M; Titz B; Gabay MT; Salton M; Dahlman KB; Tadi M; Wargo JA; Flaherty KT; Kelley MC; Misteli T; Chapman PB; Sosman JA; Graeber TG; Ribas A; Lo RS; Rosen N; Solit DB
Nature; 2011 Nov; 480(7377):387-90. PubMed ID: 22113612
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors.
Basile KJ; Le K; Hartsough EJ; Aplin AE
Pigment Cell Melanoma Res; 2014 May; 27(3):479-84. PubMed ID: 24422853
[TBL] [Abstract][Full Text] [Related]
20. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.
Das Thakur M; Salangsang F; Landman AS; Sellers WR; Pryer NK; Levesque MP; Dummer R; McMahon M; Stuart DD
Nature; 2013 Feb; 494(7436):251-5. PubMed ID: 23302800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]